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Abstract
Digital breast tomosynthesis (DBT) has shown potential to improve breast cancer
screening and diagnosis compared to digital mammography (DM). The FDA
approved DBT use in conjunction with conventional DM in 2011, but coverage
was approved by CMS recently in 2015. Given changes in coverage policies, it
is important to monitor diffusion of DBT by insurance type. This study examined
DBT trends and estimated associations with insurance type. From June 2011
to September 2014, DBT use in 22 primary care centers in the Dartmouth
-
Brigham and Women’s Hospital Population-
based Research Optimizing
Screening through Personalized Regimens research center (PROSPR) was

examined among women aged 40–89. A longitudinal repeated measures analysis
estimated the proportion of DBT performed for screening or diagnostic indications
over time and by insurance type. During the study period, 93,182 mammograms
were performed on 48,234 women. Of these exams, 16,506 DBT tests were
performed for screening (18.1%) and 2537 were performed for diagnosis (15.7%).
Between 2011 and 2014, DBT utilization increased in all insurance groups.
However, by the latest observed period, screening DBT was used more frequently
under private insurance (43.4%) than Medicaid (36.2%), Medicare (37.8%),
other (38.6%), or no insurance (32.9%; P < 0.0001). No sustained differences
in use of DBT for diagnostic testing were seen by insurance type. DBT is
increasingly used for breast cancer screening and diagnosis. Use of screening
DBT may be associated with insurance type. Surveillance is required to ensure
that disparities in breast cancer screening are minimized as DBT becomes more
widely available.

Introduction
Breast cancer is the second leading cause of mortality for
women, and optimal strategies to detect early-stage cancer—without increasing the risk for overdiagnosis—continue to be investigated. National Cancer Institute
Surveillance, Epidemiology and End Results Program
(SEER) data document higher risks for late-stage cancer
presentation and breast cancer mortality for women who
are uninsured and who have Medicaid insurance, compared
to commercially insured patients, underscoring the need
1102

to improve access to effective screening technologies in
these vulnerable groups [1].
To this end, digital breast tomosynthesis (DBT) is potentially an effective technology to aid the detection and
diagnosis of breast cancer. The DBT technique reconstructs
multiple-
dimensional X-
ray images of thin breast tissue
planes, and is thought to improve breast cancer visualization [2]. In practice, early observational data suggest a
benefit to adding DBT to conventional two-
dimensional
digital mammography (DM), including improved cancer
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detection and reduced call-
back rates for false-
positive
results [3, 4, 5]. Breast cancer simulation models suggest
adding DBT to DM may be cost-
effective in a clinical
population of women with dense breast [6]. Among women
with heterogeneously and extremely dense breasts, the
incremental cost of adding DBT imaging to screen for
breast cancer has been estimated at $53,893 per quality-
adjusted life year, and after 12 rounds of screening, an
estimated 0.5 deaths and 405 false-
positive findings per
1000 women might be avoided [6]. The Food and Drug
Administration (FDA) approved use of DBT in combination with DM for breast cancer screening for all women
in 2011. However, at this writing, there are no clinical
trial data to document the impact of DBT on mortality
from breast cancer. The Centers for Medicare and Medicaid
Services (CMS) recently approved reimbursement codes
for DBT use, requiring no copayment for screening indications, although a copayment is required for diagnostic
indications [7]. Currently, performing DBT in combination
with DM is considered experimental by some commercial
insurers, and is not uniformly covered.
Clinical uncertainty over appropriate uses of DBT, and
variation in insurance coverage could contribute to access
disparities. In particular, it is not known whether insurance status contributes to early DBT utilization patterns,
and whether disparities may exist for screening or diagnostic indications. Our current study uses data from 22
primary care centers to (1) describe the uptake of DBT
imaging since FDA approval in 2011, and (2) investigate
the role of insurance type as a potential driver of patterns
of DBT utilization in practices with access to DBT.

Methods
Study cohort and setting
The study cohort included women from 22 primary care
centers undergoing breast imaging at one of the nine
affiliated radiology facilities that offered DBT in addition
to conventional DM for screening or diagnostic purposes
between June 2011 and September 2014, the most recent
year for which data were available. Each facility was affiliated with one of the 22 primary care centers that participate in the Dartmouth (D) -Brigham and Women’s
Hospital (BWH) Population-
based Research Optimizing
Screening through Personalized Regimens (PROSPR) breast
cancer research center. We analyzed data on mammograms
(DBT and DM) performed among women aged 40–89 years
old. The D-BWH PROSPR research center studies primary
care populations within the Dartmouth-Hitchcock (DH)
Health system in New Hampshire and the Brigham and
Women’s Hospital affiliated clinical network in
Massachusetts.

© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Data sources and definitions
To obtain information regarding mammogram type (DBT
vs. DM) and indication for exam (screening vs. diagnostic),
multiple data abstraction procedures were used including
manual and natural language processing strategies to
abstract data from radiology information systems (RIS),
billing claim codes, and from the electronic health record
(EHR). Descriptions of these data collection procedures
have been published previously, and demonstrate successful
identification of indication data for DBT mammography
[8, 9]. The insurance type (private/commercial insurance,
Medicaid, Medicare, uninsured, or other payment) associated with each mammogram was obtained from the EHR.
We used EHR data and Census data to measure other
covariates thought to influence DBT utilization: age at exam,
breast density, race or ethnicity (non-Hispanic white, non-
Hispanic black, non-Hispanic Asian/Pacific Islander, Hispanic,
and other/unknown race and ethnicity), the region of care
where mammograms were performed, and neighborhood
zip code median household income. Breast density was
assigned according to the American College of Radiology
Breast Imaging Reporting and Data System (BI-RADS) criteria
(almost entirely fatty, scattered fibroglandular density, heterogeneously dense, or extremely dense breasts) [10]. Among
women with an unknown breast density on their index
mammogram, we retrieved the breast density from a prior
mammogram. For women without a prior mammogram
(5119 or 5.5% of the cohort), the index study mammogram
was retained and analyzed as an “unknown” breast density.
Five-
year estimates from the 2013 US Census American
Community Survey [11] were used to classify neighborhood
zip code median household income into quartiles based on
the patient’s residential address. A region of care indicator
was included to denote that mammography was performed
at a BWH imaging facility in Massachusetts or at a southern
DH imaging facility in New Hampshire. A northern DH
radiology facility was removed from this analysis because
DBT was initially implemented for research purposes.

Statistical analysis
In accordance with FDA-approved use of tomosynthesis, all
DBT screening and diagnostic exams were conducted with
an accompanying DM exam. We reported the total number
of mammograms performed for screening and diagnostic
purposes, and the proportion of these mammograms performed as DBT during the study period, by patient characteristics. To describe the longitudinal patterns of DBT
uptake by insurance category, we conducted a repeated
measures analysis using generalized estimating equations
(GEE), with the outcome being an indicator of the mammogram (conventional DM or DBT) being a DBT. This
1103
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analysis accounted for women having multiple exams during
the study period. We described DBT utilization at 6-month
intervals to examine diffusion of DBT use over time. We
estimated associations between DBT use and insurance status
within three periods of DBT uptake: early (June 2011 to
June 2013), middle (July 2013 to June 2014), or late (July
2014 to September 2014). A logit link and binomial variance
were assumed under an exchangeable working covariance
structure. Separate analyses were done for screening and
diagnostic indications. The PROC GENMOD procedure was
used in SAS 9.4 (SAS Institute Inc. 2015. SAS® 9.4, Cary,
North Carolina, USA), with the LSMEANS option to produce
predicted proportions of DBT exams by insurance and period.

C. R. Clark et al.

Results
During the study period, 93,182 mammograms were performed on 48,234 women (Appendix 1). Table 1 presents
data on the proportion of DBT mammograms performed
by study characteristics. The median age and interquartile
range of the study cohort was 56 (49–65) years. Overall,
16,506 (17.7%) of mammograms were performed as DBT.
The proportion of screening DBT was 18.1% of all screening
mammograms (N = 76,994), and the proportion of diagnostic
mammograms was 15.7% of all diagnostic mammograms
(N = 16,188). Across all the years of study, DBT was used
to perform mammography more frequently for women with

Table 1. Proportion of mammograms performed as DBT, by cohort characteristics and exam indication.
Proportion of mammograms performed as DBT1N (%)

Cohort characteristics

All mammograms
N = 93,182

All
16,506 (17.7)
Age at Mammogram (years)
40–49
6044 (23.7)
50–74
9936 (16.2)
75 +
526 (8.6)
Race/ethnicity2
NH white
12,667 (19.6)
NH black
1153 (11.4)
NH Asian/Pacific Islander
614 (20.6)
Hispanic
1531 (12.7)
Other/unknown
541 (15.5)
Insurance type3
Private
12,070 (19.5)
Medicaid
790 (17.7)
Medicare
2549 (13.3)
Other
792 (20.1)
Uninsured
288 (7.8)
Breast density
Fatty
619 (9.5)
Scattered fibroglandular
4520 (12.7)
Heterogeneously dense
6906 (17.2)
Extremely density
1122 (19.2)
Unknown
3339 (65.2)
Neighborhood household income (zip code median)
<$61,060
4374 (19.1)
$61,060–$78,814
3847 (16.2)
$78,815–$100,429
4440 (19.9)
>$100,429
3642 (16.0)
Unknown
203 (13.9)
Region of care
BWH
8992 (11.0)
DH-South
7514 (64.3)

Screening mammograms
N = 76,994

Diagnostic mammograms
N = 16,188

13,969 (18.1)

2537 (15.7)

5079 (24.8)
8483 (16.5)
407 (8.3)

965 (19.3)
1453 (14.6)
119 (9.8)

11,039 (20.6)
867 (10.5)
531 (21.8)
1081 (10.9)
451 (15.5)

1628 (14.7)
286 (15.4)
83 (15.4)
450 (20.9)
90 (15.7)

10,459 (20.4)
550 (15.5)
2079 (13.2)
619 (19.0)
247 (8.1)

1611 (15.2)
240 (26.8)
470 (13.9)
173 (25.3)
41 (6.3)

504 (8.5)
3704 (12.4)
5920 (18.5)
939 (19.8)
2902 (65.6)

115 (20.0)
816 (14.2)
986 (12.3)
183 (16.4)
437 (62.8)

3580 (18.8)
3200 (16.3)
3892 (21.0)
3120 (16.8)
177 (15.1)

794 (20.5)
647 (15.7)
548 (14.5)
522 (12.7)
26 (9.2)

7016 (10.6)
6953 (65.4)

1976 (13.1)
561 (53.7)

DM, digital mammography (conventional); DBT, digital breast tomosynthesis; BWH, Brigham and women’s hospital; DH, Dartmouth-Hitchcock.
1Proportions are calculated as the number of DBT exams divided by the total number of mammograms performed (DBT/(DBT + DM)). All mammograms (DBT and DM) for the cohort were performed where tomosynthesis capability was available during the study period between June 2011 and
September 2014.
2The “Other” race category includes Native American and Alaskan Natives groups, which were of insufficient number to analyze separately.
3Of 93,182 mammograms, there were N = 29 mammograms with missing information for insurance status. “Other” insurance includes international
payers, disability-related insurance, and occupational accident-related insurance and other payments.
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Figure 1. This figure shows time trends in utilization of screening DBT by insurance type. *Adjusted for age at mammogram, race, region of care
(“BLINDED NAME”), breast density, and neighborhood household income. **Due to small cell sizes the first time interval is 1.75 years. ***P-values
for chi-squared tests comparing insurance types at each time interval.

private insurance coverage (19.5%) than for those with
Medicaid coverage (17.7%), Medicare coverage (13.3%), and
uninsured women (7.8%; Table 1). Overall, DBT was used
more frequently for women with extremely dense breasts
(19.2%), and women of non-Hispanic Asian/Pacific Islander
(20.6%) or non-Hispanic white (19.6%) race, while a nonlinear pattern was observed for median neighborhood income
based on residential zip codes (Table 1).
Figure 1 shows the longitudinal trend in DBT utilization for screening indication, by insurance type and adjusted
for covariates. Across all insurance groups, use of screening
DBT increased from 2.4% to 44.0% during the study
period. The highest utilization increase was seen among
exams covered by private insurance, from 2.5% in 2011
to 46.0% in 2014. Use of DBT for diagnostic purposes
increased from 2.4% to 36.9% across all insurance groups;
no sustained differences in use of diagnostic DBT were
observed by insurance type (figure not shown.)
Table 2 shows early, middle, and late phase estimates
of DBT utilization associated with insurance status for
screening and diagnostic use, respectively. During the early
phase of DBT uptake, a higher proportion of screening
mammograms were performed as DBT among Medicaid
(5.4%) and Medicare beneficiaries (3.5%) compared to
those privately insured (2.8%) or uninsured (1.0%;
P < 0.0001). However, by the late phase of DBT uptake,
screening DBT was used more frequently under private
insurance (43.4%) than Medicaid (36.2%), Medicare
(37.8%), or the uninsured (32.9%; P = 0.001). Other
factors associated with increased use of screening DBT
were younger age, higher income level, and dense breasts.
© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Table 2. Proportion of DBT (95% CI) for insurance type by exam indication for each time period1,2.

Insurance type
Early phase: June 2011–
June 2013
Private
Medicaid
Medicare
Other
Uninsured
Mid phase: July 2013–
June 2014
Private
Medicaid
Medicare
Other
Uninsured
Late phase: July 2014–
Sep 2014
Private
Medicaid
Medicare
Other
Uninsured

Screening indication

Diagnostic
indication

Proportion
DBT (95% CI)

Proportion DBT
(95% CI)

P < 0.0001

P < 0.0001

2.8 (2.6–3.0)
5.4 (4.3–6.7)
3.5 (2.9–4.2)
3.9 (2.8–5.4)
1.0 (0.7–1.6)
P < 0.0001

3.9 (3.4–4.5)
5.0 (3.4–7.3)
5.4 (4.2–6.9)
7.0 (4.5–10.1)
1.5 (0.9–2.5)
P = 0.56

16.8 (16.3–17.4)
14.1 (12.5–15.9)
13.9 (12.9–14.9)
15.7 (14.0–17.5)
12.5 (9.7–15.9)
P = 0.001

21.9 (20.5–23.4)
25.2 (21.3–29.5)
21.6 (19.1–24.4)
23.3 (19.3–28.0)
25.7 (14.1–42.2)
P = 0.95

43.4 (42.0–45.0)
36.2 (31.0–41.8)
37.8 (35.0–40.6)
38.6 (34.3–43.0)
32.9 (21.5–46.7)

36.0 (32.9–39.3)
35.9 (27.6–45.1)
37.9 (32.5–43.6)
36.0 (27.5–45.4)
29.9 (14.5–51.7)

DBT, Digital Breast Tomosynthesis.
1Models adjusted for age at mammogram, race, region of care (BWH,
DH-South), breast density, and neighborhood household income.
2P-values for chi-squared tests comparing insurance types at each time
interval.
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Similar insurance patterns of DBT uptake were found
for diagnostic indication for the early phase. No insurance
differences were found for diagnostic DBT in the middle
(P = 0.56) and late phases (P = 0.99).

Discussion
We found a rapid increase in the use of DBT in 22 primary care practices in Massachusetts and New Hampshire
from 2011 to 2014. By late 2014, screening DBT use varied
by insurance status during all periods, and in the late
period, ranged from 32.9% among the uninsured to 43.4%
among privately insured women. No sustained differences
in diagnostic DBT use were seen by insurance status.
There are few data on utilization of DBT across the
US. Data from a 2012 survey of physician radiologist
members of the Society of Breast Imaging (SBI) estimated
30% of respondents used DBT for either screening or
diagnostic purposes [12]. The SBI data report that DBT
use in this early phase of uptake was highest in academic
medical practices and in the northeast US. Our results
may reflect higher utilization compared to other regions
of the country. Our findings of increasing disparities
between uninsured, publically insured, and privately
insured women may reflect uncertainty about methods
for billing for this technology. Of interest from the 2012
survey, radiology respondents who used DBT reported
that patients were required to sign a waiver accepting
costs for DBT that were not covered by insurance, and
that noncovered costs may have been charged to patients.
Our study has several limitations, including the geographic
sampling frame, the inability to assess copayment charges,
deductible levels for insurance plans, or other cost drivers
of utilization that would give context to explain our results.
Additionally, we note that the study period does not reflect
the impact of newly assigned DBT billing codes from CMS,
which may increase availability of DBT, and reduce uncovered costs for publically insured women. In our assessment
of breast density as a correlate of DBT use, we were able
to obtain breast density information on the vast majority
of mammograms. However, we note that 4.1% of mammograms had breast density assigned based on a prior
mammogram, which reflects a limitation of our data abstraction procedures. Breast density notification legislation is not
likely to have played any role in the DBT utilization patterns
we report since there was no legislation in effect within
the study area throughout the study period, although MA
enacted such a law that went into effect January 1, 2015.
Several strengths of our study include a longitudinal
design, the ability to obtain direct measurement of mammography utilization from EMR and claims data, and a
large sample with detailed measures of covariates that may
influence estimates of the association between insurance
type and DBT use.
1106
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We conclude that DBT is increasingly used to perform
mammography in the settings we studied, consistent with
earlier survey data suggesting increasing popularity of the
technology. Additional data are required to recommend
DBT as an approach for screening to improve health
outcomes. However, we find that use of DBT for screening in primary care sites may be patterned by insurance
status. Surveillance is required to ensure that insurance
status differences in access to DBT do not contribute to
disparities in breast cancer screening as DBT technology
becomes more widely available.
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Appendix 1
Number of study participants (N = 48,234), and number of mammograms performed (N = 93,182), by women’s
characteristics at the time the mammogram was performed.

Women’s characteristics
Age at mammogram (years)
40–49
50–74
75+
Race/ethnicity1
White, non-Hispanic
Black, non-Hispanic
Asian/Pacific Islander, non-Hispanic
Hispanic
Other/unknown
Insurance type2
Private
Medicaid
Medicare
Other
Uninsured
Breast density
Fatty
Scattered fibroglandular
Heterogeneously dense
Extremely dense
Unknown
Neighborhood household income (zip code median)
<$61,060
$61,060–$78,814
$78,815–$100,429
>$100,429
Unknown
Region of care
BWH
DH-South

Total number of study participants
N = 48,234
N (%)

Total number of mammograms (DM
or DBT) N = 93,182
N (%)

14,709 (30.5)
30,591 (63.4)
2934 (6.1)

25,518 (27.4)
61,529 (66.0)
6135 (6.6)

34,464 (71.5)
4847 (10.0)
1601 (3.3)
5622 (11.7)
1700 (3.5)

64,539 (69.3)
10,091 (10.8)
2981 (3.2)
12,084 (13.0)
3487 (3.7)

33,180 (68.8)
1894 (3.9)
8819 (18.3)
1634 (3.4)
2685 (5.6)

61,935 (66.5)
4453 (4.8)
19,110 (20.5)
3944 (4.2)
3711 (4.0)

2952 (6.1)
17,634 (36.5)
20,283 (42.1)
2872 (6.0)
4493 (9.3)

6499 (7.5)
35,618 (40.8)
40,098 (45.0)
5848 (6.7)
5119 (5.5)

12,289 (25.5)
11,973 (24.8)
12,188 (25.3)
11,035 (22.9)
749 (1.6)

18,678 (24.6)
24,219 (25.5)
23,205 (23.9)
25,624 (24.4)
1456 (1.6)

37,762 (78.3)
10,472 (21.7)

81,504 (87.5)
11,678 (12.5)

DM, digital mammography; DBT, digital breast tomosynthesis; DX, diagnostic; NH, non-Hispanic; BWH, Brigham and women’s hospital;
DH, Dartmouth-Hitchcock.
All mammograms (DBT and DM) for the cohort were performed where tomosynthesis capability was available during the study period between June
2011 and September 2014.
1The “Other” race category includes Native American and Alaskan Natives groups, which were of insufficient number to analyze separately.
2Missing (N): Insurance type (26 women, 29 mammograms). “Other” insurance includes international payers, disability-related insurance, and
occupational accident-related insurance and other payments.
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